BAM
AUTL

Byrne Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Byrne Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160 Hold
100
– – ﹤0.01% 576
2026
Q1 		$138 Hold
100
– – ﹤0.01% 550
2025
Q4 		$199 Sell
100
-125
-56% -$192 ﹤0.01% 544
2025
Q3 		$367 Hold
225
– – ﹤0.01% 548
2025
Q2 		$513 Sell
225
-25
-10% -$41 ﹤0.01% 531
2025
Q1 		$388 Hold
250
– – ﹤0.01% 547
2024
Q4 		$588 Sell
250
-1,150
-82% -$3.89K ﹤0.01% 525
2024
Q3 		$5.08K Sell
1,400
-100
-7% -$399 ﹤0.01% 454
2024
Q2 		$5K Sell
1,500
-300
-17% -$1.29K ﹤0.01% 442
2024
Q1 		$11.5K Sell
1,800
-900
-33% -$5.61K 0.01% 349
2023
Q4 		$17.9K Buy
+2,700
New +$10.3K 0.01% 304

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Byrne Asset Management's AUTL Position: Q2 2026 in Review

Byrne Asset Management held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 100 shares worth $160. The position accounts for ﹤0.01% of the portfolio, ranked #576.

Byrne Asset Management first reported a position in AUTL in Q4 2023 and has held it in 11 quarters since. The position peaked at $17.9K in Q4 2023. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Byrne Asset Management held 100 shares of Autolus Therapeutics worth $160 as of Q2 2026.
  • Byrne Asset Management left its Autolus Therapeutics share count unchanged in Q2 2026.
  • Autolus Therapeutics made up ﹤0.01% of Byrne Asset Management's portfolio in Q2 2026, its #576 holding.
  • Byrne Asset Management first reported a position in Autolus Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Byrne Asset Management's Autolus Therapeutics position peaked at $17.9K in Q4 2023.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.